Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
RO4893594, Lucentis 10 mg/ml solution for injection in pre-filled syringe, RO4893594
Hoffmann-La Roche
Neovascular Age-Related Macular Degeneration (nAMD)
1 trial -
RO4893594, RO4893594, Lucentis 10 mg/ml solution for injection in pre-filled syringe
Hoffmann-La Roche
Neovascular age-related macular degeneration (nAMD)
1 trial -
ROSUVASTATIN, INCLISIRAN, ATORVASTATIN, ATORVASTATIN, Placebo to KJX839 (Inclisiran sodium) 0 mg/1.5 mL solution for injection in pre-filled syringe, ROSUVASTATIN, ATORVASTATIN, ATORVASTATIN, ROSUVASTATIN, ROSUVASTATIN
Novartis Pharmaceuticals
Atherosclerotic cardiovascular disease (ASCVD)
1 trial -
ROSUVASTATIN, ROSUVASTATIN, INCLISIRAN, Placebo to KJX839 (Inclisiran sodium) 0 mg/1.5 mL solution for injection in pre-filled syringe, ROSUVASTATIN, ATORVASTATIN, ATORVASTATIN, ROSUVASTATIN, ATORVASTATIN, ATORVASTATIN
Novartis Pharmaceuticals
Non-obstructive Coronary Artery Disease
1 trial -
Reblozyl 75 mg powder for solution for injection, Reblozyl 25 mg powder for solution for injection
Celgene Europe Limited
myelodysplastic syndrome (MDS); beta (β)-thalassemia (THAL); myelofibrosis (MF)
1 trial -
Reblozyl 75 mg powder for solution for injection, Reblozyl 25 mg powder for solution for injection
Celgene Europe Limited
Myelodysplastic syndrome
1 trial -
Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Acute Gout
2 trials -
Recombinant Human Albumin Injection
The First People's Hospital of Lianyungang
Hepatic Ascites
2 trials -
Remodulin (treprostinil sodium) Injection
United Therapeutics Europe Ltd
Peripheral Vascular Disease
1 trial -
Remodulin® (treprostinil sodium) Injection
United Therapeutics Europe Ltd
Critical Limb Ischemia
1 trial -
Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, Enbrel 25 mg solution for injection in pre-filled syringe, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, Enbrel 10 mg powder and solvent for solution for injection for paediatric use, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempi
The George Institute
juvenile idiopathic arthritis
1 trial -
Revatio 0.8 mg/ml solution for injection
Pari Pharma GmbH
Hypoxic ischemic encephalopathy
1 trial -
Revlimid 10 mg hard capsules, DIPHENHYDRAMINE , Revlimid 20 mg hard capsules, Dexamethasone 3.3 mg/ml solution for injection, Zelvina 5 mg hard capsules, Revlimid 10 mg hard capsules, Isatuximab, Revlimid 25 mg hard capsules, Zelvina 25 mg hard capsules, Revlimid 5 mg hard capsules, Revlimid 15 mg hard capsules, Zelvina 10 mg hard capsules, PARACETAMOL , Zelvina 20 mg hard capsules, MONTELUKAST , METHYLPREDNISOLONE , Revlimid 5 mg hard capsules, Revlimid 20 mg hard capsules, Zelvina 15 mg hard capsules, Isa
Sanofi-aventis Healthcare Pty Ltd
Plasma cell myeloma
1 trial -
Revlimid 10 mg hard capsules, Zelvina 10 mg hard capsules, MINJUVI 200 mg powder for concentrate for solution for infusion, Zelvina 15 mg hard capsules, Revlimid 5 mg hard capsules, Zelvina 5 mg hard capsules, Revlimid 20 mg hard capsules, 0.9% saline solution for infusion. The placebo (250 mL infusion container with 0.9% (w/v) sodium chloride for injection) is being sourced locally from commercial market and delivered to an unblinded pharmacy., Revlimid 15 mg hard capsules, Truxima 100 mg concentrate for s
Incyte
follicular lymphoma (FL) and marginal zone lymphoma (MZL)
1 trial -
Revlimid 20 mg hard capsules, Dexamethason 4 mg JENAPHARM®, VELCADE 3.5 mg powder for solution for injection, DEXAMETHASONE , Revlimid 25 mg hard capsules, Revlimid 5 mg hard capsules, Revlimid 15 mg hard capsules, Revlimid 15 mg hard capsules, Revlimid 5 mg hard capsules, Revlimid 10 mg hard capsules, Revlimid 10 mg hard capsules, DARZALEX 1800 mg solution for injection
Janssen-Cilag International N.V.
Multiple Myeloma
1 trial -
Revlimid 25 mg hard capsules, Revlimid 5 mg hard capsules, Zelvina 15 mg hard capsules, Dexamethasone 3.3 mg/ml solution for injection, Zelvina 25 mg hard capsules, Revlimid 20 mg hard capsules, Revlimid 5 mg hard capsules, Isatuximab, Zelvina 10 mg hard capsules, Revlimid 10 mg hard capsules, DexaGalen® 8 mg injekt Injektionslösung, Revlimid 15 mg hard capsules, Revlimid 10 mg hard capsules, Zelvina 20 mg hard capsules, Dexamethason 4 mg JENAPHARM®, Zelvina 5 mg hard capsules, Revlimid 25 mg hard capsules,
Sanofi-aventis Healthcare Pty Ltd
Cancer
1 trial -
Risankizumab, Placebo for Risankizumab Solution for injection in prefilled syringe, ABBV-066
AbbVie Deutschland GmbH & Co. KG
Psoriatic Arthritis
1 trial -
Risankizumab, Risankizumab placebo solution for infusion, ABBV-066 / Risankizumab, ABBV-066, Risankizumab placebo solution for injection in pre-filled syringe, Risankizumab
AbbVie Deutschland GmbH & Co. KG
Ulcerative Colitis
1 trial -
RoActemra 20 mg/mL concentrate for solution for infusion, MabThera 500 mg concentrate for solution for infusion, Vincristine Sulfate 1 mg/ml solution for injection, Neulasta 6 mg solution for injection, AZD0486, RoActemra 20 mg/mL concentrate for solution for infusion, Truxima 500 mg concentrate for solution for infusion, Ribodoxo® 2 mg/ml Injektionslösung, Prednison 20 mg GALEN®, AZD0486, Endoxan 500 mg, poeder voor oplossing voor injectie, Ruxience 500 mg concentrate for solution for infusion
AstraZeneca AB
Large B-cell Lymphoma
1 trial -
Rozanolixizumab, also known as UCB7665, Rystiggo 140 mg/ml solution for injection, -
Lacuna Pharma Pty Ltd
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-AD)
1 trial -
Rusfertide 45mg, Rusfertide 60mg, Rusfertide 30mg, Rusfertide 10mg, Rusfertide 20mg, Placebo to Match PTG-300 for Injection. Formulation (lyophilized powder) is based upon that of PTG-300 for Injection, with the drug substance omitted.
Protagonist Therapeutics, Inc
Polycythemia Vera
1 trial -
Ryzodeg 100 units/mL FlexTouch solution for injection in pre-filled pen, IcoSema 700 U/mL + 2 mg/mL PDS290
NovoThirteen
Type 2 diabetes
1 trial -
SANDOSTATIN LAR 10 mg powder and solvent for suspension for injection, LysaKare 25 g/25 g solution for infusion, SANDOSTATIN LAR 20 mg powder and solvent for suspension for injection, SANDOSTATIN LAR 30 mg powder and solvent for suspension for injection, Lutathera 370 MBq/mL solution for infusion
Advanced Accelerator Applications
Patients with somatostatin receptor positive, well-differentiated G2 and G3, advanced GEP NETs
1 trial -
SODIUM CHLORIDE, Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)
Pari Pharma GmbH
HPV vaccine
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources